We are live on !
Find out more
Marshall Wace Portfolio holdings
AUM
$127B
Turnover
40.17%
1-Year Est. Return
46.06%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+787.47%
AUM
$127B
AUM Growth
+$26.3B
(+26%)
Cap. Flow
+$9.28B
Cap. Flow % of AUM
Cap. Flow %
7.32%
Top 10 Holdings %
Top 10 Hldgs %
37.66%
Holding
3,898
New
771
Increased
1,083
Reduced
1,182
Closed
795
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
2.3
years
Top 20 Avg Time Held
Equity + Options
1.6
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
2.4
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$9.9B |
| 2 |
Costco
COST
|
+$907M |
| 3 |
AbbVie
ABBV
|
+$643M |
| 4 |
JPMorgan Chase
JPM
|
+$609M |
| 5 |
Bank of America
BAC
|
+$567M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.03B |
| 2 |
Mercado Libre
MELI
|
+$528M |
| 3 |
Broadcom
AVGO
|
+$514M |
| 4 |
Sandisk
SNDK
|
+$507M |
| 5 |
Marvell Technology
MRVL
|
+$499M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 34.91% |
| 2 | Technology | 20.64% |
| 3 | Consumer Discretionary | 9.1% |
| 4 | Healthcare | 8.21% |
| 5 | Financials | 7.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1726
WD-40
WDFC
$2.85B
| $2.44M | ﹤0.01% |
10,019
-108,369
| -92% | -$23.2M |
2022 Q3
15 quarters
|
|
1727
Enerpac Tool Group
EPAC
$1.83B
| $2.43M | ﹤0.01% |
67,699
-114,239
| -63% | -$4.01M |
2025 Q3
3 quarters
|
|
1728
Cartesian Therapeutics
RNAC
$187M
| $2.43M | ﹤0.01% |
232,919
-18,196
| -7% | -$135K |
2025 Q1
5 quarters
|
|
1729
iRadimed
IRMD
$1.1B
| $2.42M | ﹤0.01% |
+25,298
| New | +$2.3M |
2026 Q2
0 quarters
|
|
1730
Milestone Pharmaceuticals
MIST
$80.7M
| $2.41M | ﹤0.01% |
1,797,695
-146,835
| -8% | -$235K |
2025 Q3
3 quarters
|
|
1731
NovaBridge Biosciences American Depositary Shares
NBP
$158M
| $2.4M | ﹤0.01% |
+1,231,946
| New | +$2.51M |
2026 Q2
0 quarters
|
|
1732
Activate Energy Acquisition Corp
AEAQ
| $2.4M | ﹤0.01% |
240,000
| – | – |
2026 Q1
1 quarter
|
|
1733
Curtiss-Wright
CW
$17.2B
| $2.39M | ﹤0.01% |
+3,160
| New | +$2.32M |
2026 Q2
0 quarters
|
|
1734
CBIZ
CBZ
$3.02B
| $2.39M | ﹤0.01% |
74,383
+54,361
| +272% | +$1.69M |
2025 Q2
4 quarters
|
|
1735
iShares MSCI Saudi Arabia ETF
KSA
$544M
| $2.38M | ﹤0.01% |
+63,897
| New | +$2.48M |
2026 Q2
0 quarters
|
|
1736
Primo Brands
PRMB
$7.13B
| $2.38M | ﹤0.01% |
97,522
-235,536
| -71% | -$5.23M |
2025 Q4
2 quarters
|
|
1737
Primis Financial Corp
FRST
$379M
| $2.38M | ﹤0.01% |
145,343
+116,099
| +397% | +$1.69M |
2025 Q4
2 quarters
|
|
1738
National Vision
EYE
$1.48B
| $2.38M | ﹤0.01% |
125,106
+5,826
| +5% | +$119K |
2023 Q1
13 quarters
|
|
1739
AppFolio
APPF
$7.46B
| $2.38M | ﹤0.01% |
14,830
-78,941
| -84% | -$12.6M |
2025 Q1
5 quarters
|
|
1740
Texas Capital Bancshares
TCBI
$4.43B
| $2.37M | ﹤0.01% |
22,923
+16,123
| +237% | +$1.62M |
2026 Q1
1 quarter
|
|
1741
iShares Russell 1000 Value ETF
IWD
$84.2B
| $2.36M | ﹤0.01% |
+9,753
| New | +$2.27M |
2026 Q2
0 quarters
|
|
1742
Capricor Therapeutics
CAPR
$345M
| $2.36M | ﹤0.01% |
98,185
-11,346
| -10% | -$344K |
2025 Q2
4 quarters
|
|
1743
Mid Penn Bancorp
MPB
$868M
| $2.36M | ﹤0.01% |
67,846
+50,996
| +303% | +$1.69M |
2025 Q4
2 quarters
|
|
1744
Gorilla Technology Group
GRRR
$230M
| $2.36M | ﹤0.01% |
+118,634
| New | +$1.78M |
2026 Q2
0 quarters
|
|
1745
TFS Financial
TFSL
$4.66B
| $2.35M | ﹤0.01% |
+132,607
| New | +$2.07M |
2026 Q2
0 quarters
|
|
1746
Ormat Technologies
ORA
$5.36B
| $2.34M | ﹤0.01% |
21,499
+17,449
| +431% | +$2.16M |
2025 Q1
5 quarters
|
|
1747
Endeavour Silver
EXK
$2.21B
| $2.34M | ﹤0.01% |
282,199
-155,388
| -36% | -$1.45M |
2026 Q1
1 quarter
|
|
1748
Huron Consulting
HURN
$3.11B
| $2.34M | ﹤0.01% |
25,900
+17,310
| +202% | +$1.98M |
2026 Q1
1 quarter
|
|
1749
First Trust NASDAQ Technology Dividend Index Fund
TDIV
$4.42B
| $2.33M | ﹤0.01% |
+20,317
| New | +$2.25M |
2026 Q2
0 quarters
|
|
1750
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$46.6B
| $2.33M | ﹤0.01% |
14,700
-1,865,700
| -99% | -$278M |
2024 Q3
7 quarters
|
|
Similar funds
Marshall Wace's Q2 2026 Portfolio in Review
As of Q2 2026, Marshall Wace held 3,898 positions worth $127B, up 26% from $100B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Marshall Wace deployed $9.28B of net new capital in Q2 2026, opening 771 new positions and adding to 1,083 existing holdings. Its largest new stake was LPL Financial: 975,627 shares worth $275M.
By sector, the portfolio is most concentrated in Miscellaneous at 35% of assets, up from 30% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $1.03B trimmed.
- Marshall Wace's largest Q2 2026 buy was LPL Financial: 975,627 shares worth $275M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.9B increase.
- Marshall Wace's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.03B.
- Marshall Wace fully exited Merck in Q2 2026, selling an estimated $325M.
- Marshall Wace's ten largest holdings make up 38% of its $127B portfolio in Q2 2026.
- Marshall Wace opened 771 new positions and closed 795 in Q2 2026.
- Marshall Wace's portfolio value rose 26% quarter-over-quarter to $127B.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.